Core Viewpoint - Nuo Cheng Jian Hua's stock price has shown significant volatility, with a year-to-date increase of 94.22%, but a recent decline of 3.68% over the last five trading days, indicating potential market fluctuations and investor sentiment shifts [2]. Company Overview - Nuo Cheng Jian Hua, established on November 3, 2015, and listed on September 21, 2022, is a Chinese biopharmaceutical company focused on the research, production, and commercialization of drugs, particularly in oncology and autoimmune diseases [2]. - The company's product pipeline includes ICP-022, ICP-B04, ICP-490, ICP-192, and ICP-723, targeting unmet clinical needs [2]. - The revenue composition is primarily from drug sales (87.67%), followed by technology licensing (12.04%), and minimal contributions from testing and R&D services (0.15% each) [2]. Financial Performance - For the period from January to September 2025, Nuo Cheng Jian Hua reported a revenue of 1.115 billion yuan, reflecting a year-on-year growth of 59.85%, while the net profit attributable to shareholders was a loss of 64.415 million yuan, an improvement of 76.61% compared to the previous period [3]. - As of September 30, 2025, the number of shareholders increased by 8.66% to 16,500, indicating growing interest in the company [3]. Shareholder Composition - The top ten circulating shareholders include notable funds such as Fu Guo Precision Medical Flexible Allocation Mixed A and Wan Jia You Xuan, with some new entrants and changes in holdings among existing shareholders [3].

Core Viewpoint - Kelong Pharmaceutical's stock price has shown fluctuations, with a year-to-date increase of 11.42%, but recent declines over various trading periods indicate potential volatility in investor sentiment [1][2]. Company Overview - Kelong Pharmaceutical, established on May 29, 2002, and listed on June 3, 2010, is based in Chengdu, Sichuan Province. The company specializes in the development, production, and sales of large-volume infusion products [1]. - The revenue composition of Kelong Pharmaceutical includes: non-infusion products (48.37%), infusion products (41.28%), research and development projects (7.01%), and others (3.33%) [1]. Financial Performance - For the period from January to September 2025, Kelong Pharmaceutical reported a revenue of 13.277 billion yuan, a year-on-year decrease of 20.92%. The net profit attributable to shareholders was 1.201 billion yuan, down 51.41% year-on-year [2]. - Cumulatively, Kelong Pharmaceutical has distributed 6.898 billion yuan in dividends since its A-share listing, with 3.587 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Kelong Pharmaceutical had 37,100 shareholders, an increase of 8.35% from the previous period. The average number of circulating shares per shareholder was 35,200, a decrease of 7.70% [2]. - The top ten circulating shareholders include various funds, with notable changes in holdings, such as a decrease in shares held by major institutional investors [3].

Core Viewpoint - Nanmo Bio has experienced significant stock price fluctuations in 2023, with a year-to-date increase of 79.28% but recent declines in the short term [1] Company Overview - Nanmo Bio, officially known as Shanghai Nanmo Biological Technology Co., Ltd., was established on September 20, 2000, and went public on December 28, 2021 [1] - The company specializes in the research, production, and sales of genetically modified animal models and related technical services [1] - Revenue composition includes standardized models (48.34%), model technical services (21.92%), model breeding (19.50%), customized models (9.34%), and others (0.91%) [1] Financial Performance - For the period from January to September 2025, Nanmo Bio reported a revenue of 303 million yuan, representing a year-on-year growth of 14.29% [2] - The net profit attributable to shareholders reached 26.76 million yuan, showing a substantial year-on-year increase of 276.14% [2] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 2.53% to 6,687, while the average circulating shares per person decreased by 2.47% to 11,658 shares [2] - Since its A-share listing, Nanmo Bio has distributed a total of 30.04 million yuan in dividends, with 10.00 million yuan distributed over the past three years [3] - Among the top ten circulating shareholders, Tianhong Medical Health A is a new entrant, holding 377,400 shares [3]

Core Viewpoint - As of November 21, Osai Kang's stock price has decreased by 2.10%, with a current price of 16.78 CNY per share, reflecting a significant decline in recent trading days despite a year-to-date increase of 33.28% [1] Financial Performance - For the period from January to September 2025, Osai Kang achieved a revenue of 1.434 billion CNY, representing a year-on-year growth of 3.57%. The net profit attributable to shareholders was 223 million CNY, showing a substantial increase of 75.81% [2] Shareholder Information - As of November 10, the number of shareholders for Osai Kang reached 30,000, an increase of 8.50% from the previous period. The average number of circulating shares per person decreased by 7.83% to 30,917 shares [2] Dividend Distribution - Since its A-share listing, Osai Kang has distributed a total of 721 million CNY in dividends, with 111 million CNY distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, among the top ten circulating shareholders, Yongying Medical Innovation Mixed Fund A increased its holdings by 9.27 million shares to 20.95 million shares, while new shareholders such as Yongying Ruixin Mixed Fund A and Yongying Stable Enhanced Bond A entered the top ten list [3]

Core Viewpoint - Nocare Biopharma's stock has experienced fluctuations, with a year-to-date increase of 92.83% but a recent decline of 6.55% over the past five trading days [1] Company Overview - Nocare Biopharma, established on November 3, 2015, and listed on September 21, 2022, is based in Beijing and focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [1] - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and 0.15% each from testing and research services [1] Financial Performance - For the period from January to September 2025, Nocare Biopharma reported revenue of 1.115 billion yuan, reflecting a year-on-year growth of 59.85%, while the net profit attributable to shareholders was -64.41 million yuan, an increase of 76.61% year-on-year [2] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 8.66% to 16,500, with an average of 0 circulating shares per person [2] - The top ten circulating shareholders include several new entrants, such as Wanjiayou Xuan and Ping An Healthcare, while some previous shareholders have exited the list [3]

Core Points - Boda Pharmaceutical's stock price decreased by 2.08% on November 21, reaching 49.06 CNY per share, with a market capitalization of 20.641 billion CNY [1] - The company has experienced a year-to-date stock price decline of 8.69%, with a 9.68% drop over the last five trading days and a 23.44% decline over the past 60 days [1] - As of September 30, 2025, Boda Pharmaceutical reported a revenue of 2.717 billion CNY, a year-on-year increase of 15.90%, while the net profit attributable to shareholders decreased by 23.86% to 317 million CNY [2] Financial Performance - The company has distributed a total of 669 million CNY in dividends since its A-share listing, with 184 million CNY distributed over the last three years [3] - As of September 30, 2025, the number of shareholders decreased by 7.99% to 29,500, while the average number of circulating shares per person increased by 8.68% to 14,198 shares [2] Shareholder Structure - Among the top ten circulating shareholders, Xingshan Commercial Model Mixed Fund A is the fifth largest with 5.827 million shares, marking a new entry [3] - E Fund's Growth Enterprise Board ETF, ranked sixth, reduced its holdings by 912,300 shares to 5.456 million shares [3] - Xingshan Helun Mixed Fund A is the seventh largest shareholder with 5.402 million shares, also a new entry [3]

Core Viewpoint - Zai Lab's stock price has shown significant volatility, with a year-to-date increase of 64.82%, but a recent decline of 3.11% over the past five trading days, indicating potential market fluctuations and investor sentiment shifts [1][2]. Company Overview - Zai Lab, established on March 18, 2009, and listed on January 23, 2020, is based in Kunshan, Jiangsu Province, focusing on the research, production, and sales of chemical and biological new drugs [1]. - The company's main revenue source is pharmaceuticals, accounting for 99.97% of its business, with minimal contributions from intermediates and asset leasing [1]. Financial Performance - For the period from January to September 2025, Zai Lab reported a revenue of 593 million yuan, reflecting a year-on-year growth of 54.49%. However, the net profit attributable to shareholders was a loss of 93.42 million yuan, showing a slight increase in loss of 4.58% compared to the previous period [2]. Shareholder Structure - As of September 30, 2025, Zai Lab had 8,809 shareholders, a slight increase of 0.16% from the previous period. The average number of circulating shares per shareholder decreased by 0.16% to 30,049 shares [2]. - Notable institutional shareholders include China Europe Medical Health Mixed A and ICBC Frontier Medical Stock A, with varying changes in their holdings [2].

Core Viewpoint - Benda Pharmaceutical's stock has experienced a decline in recent trading sessions, with a notable drop in both share price and market capitalization, indicating potential challenges in the company's performance and investor sentiment [1][2]. Company Performance - As of September 30, Benda Pharmaceutical reported a revenue of 2.717 billion yuan, reflecting a year-on-year growth of 15.90%. However, the net profit attributable to shareholders decreased by 23.86% to 317 million yuan [2]. - The company's stock price has fallen by 5.40% year-to-date, with a 5.71% decline over the past five trading days, a 12.75% drop over the last 20 days, and a significant 27.60% decrease over the past 60 days [1]. Shareholder Information - The number of shareholders decreased by 7.99% to 29,500, while the average number of circulating shares per person increased by 8.68% to 14,198 shares [2]. - Benda Pharmaceutical has distributed a total of 669 million yuan in dividends since its A-share listing, with 184 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, notable institutional shareholders include Xingquan Commercial Model Mixed Fund (LOF) A, which is the fifth-largest shareholder with 5.827 million shares, and E-Fund's Growth Enterprise Board ETF, which has reduced its holdings by 912,300 shares [3].

Core Viewpoint - The stock of Jibeier has experienced a decline recently despite a year-to-date increase, indicating potential volatility in its market performance [2]. Group 1: Stock Performance - As of November 19, Jibeier's stock price decreased by 2.00%, trading at 29.33 CNY per share with a total market capitalization of 5.849 billion CNY [1]. - Year-to-date, Jibeier's stock has risen by 34.05%, but it has seen a decline of 5.99% over the last five trading days, 8.00% over the last 20 days, and 21.28% over the last 60 days [2]. Group 2: Company Overview - Jibeier Pharmaceutical Co., Ltd. was established on November 13, 2001, and went public on May 18, 2020. The company specializes in the research, production, and sales of pharmaceuticals [2]. - The main revenue sources for Jibeier include Likujun tablets (72.72%), Nigulol tablets (14.20%), Yipingfeng capsules (4.88%), and others [2]. Group 3: Financial Performance - For the period from January to September 2025, Jibeier reported a revenue of 704 million CNY, reflecting a year-on-year growth of 9.52%, and a net profit attributable to shareholders of 197 million CNY, which is a 12.80% increase year-on-year [2]. - Since its A-share listing, Jibeier has distributed a total of 476 million CNY in dividends, with 252 million CNY distributed over the past three years [3]. Group 4: Shareholder Information - As of September 30, 2025, Jibeier had 7,742 shareholders, an increase of 28.97% from the previous period, with an average of 25,759 circulating shares per shareholder, a decrease of 22.46% [2]. - Notable new institutional shareholders include Caitong Advantage Industry Rotation Mixed Fund and GF Healthcare Stock A, holding 1.2392 million shares and 959,000 shares respectively [3].

Core Viewpoint - Nocera Biopharma's stock has experienced fluctuations, with a year-to-date increase of 95.03% but a recent decline of 4.77% over the past five trading days [1] Company Overview - Nocera Biopharma, established on November 3, 2015, and listed on September 21, 2022, is based in Beijing and focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [1] - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and 0.15% each from testing and research services [1] Financial Performance - For the period from January to September 2025, Nocera Biopharma reported a revenue of 1.115 billion yuan, reflecting a year-on-year growth of 59.85%, while the net profit attributable to shareholders was -64.41 million yuan, an increase of 76.61% compared to the previous period [2] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 8.66% to 16,500, with an average of 0 circulating shares per shareholder [2] - The top ten circulating shareholders include several new entrants, such as Wan Jia You Xuan and Ping An Medical Health, while some previous shareholders have reduced their holdings [3]